This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy
by Zacks Equity Research
Immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis.
DVAXNegative Net Change ETONNegative Net Change IMMXNegative Net Change
biotechnology biotechs
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
by Zacks Equity Research
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
DVAXNegative Net Change CORTNegative Net Change MBRXPositive Net Change BTTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
by Zacks Equity Research
Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.
CORTNegative Net Change ANIKNegative Net Change PBYINegative Net Change ANVSNegative Net Change
biotechnology medical
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
by Zacks Equity Research
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
CORTNegative Net Change ANIKNegative Net Change RLMDNegative Net Change ANVSNegative Net Change
biotechnology medical
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
by Zacks Equity Research
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change EVAXNegative Net Change
biotechnology medical
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) plunges on a surprise CRL by the FDA for its nasal spray curated for allergic reactions.
DVAXNegative Net Change ETONNegative Net Change SPRYPositive Net Change
biotechnology
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
by Zacks Equity Research
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
DVAXNegative Net Change CORTNegative Net Change AQSTNegative Net Change BTTXNo Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
by Zacks Equity Research
Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.
GSKNegative Net Change MRNANegative Net Change PTCTNegative Net Change SPRYPositive Net Change
biotechnology
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
by Zacks Equity Research
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
DVAXNegative Net Change CORTNegative Net Change ATRANegative Net Change BTTXNo Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
by Zacks Equity Research
Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.
CORTNegative Net Change ANIKNegative Net Change MRNSPositive Net Change ANVSNegative Net Change
biotechnology medical
Should You Buy ProAssurance (PRA) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PRANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M
by Zacks Equity Research
Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.
ANIKNegative Net Change ANIPNegative Net Change ANVSNegative Net Change ELUTPositive Net Change
biotechnology medical
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
by Zacks Equity Research
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
GSKNegative Net Change DVAXNegative Net Change INCYNegative Net Change EXELNegative Net Change
biotechnology biotechs
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy.
ANIKNegative Net Change PTCTNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology medical
Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use
by Zacks Equity Research
Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.
VRTXNegative Net Change ANIKNegative Net Change CRSPNegative Net Change ANVSNegative Net Change
biotechnology crispr medical
Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week
by Zacks Equity Research
Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.
DVAXNegative Net Change EXELNegative Net Change RCKTNegative Net Change
biotechnology biotechs pharmaceuticals
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
by Zacks Equity Research
Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.
BMYNegative Net Change GILDNegative Net Change MRNANegative Net Change RCKTNegative Net Change BCYCPositive Net Change
biotechnology biotechs
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
by Zacks Equity Research
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
ANIKNegative Net Change VKTXNegative Net Change MDGLNegative Net Change AKRONegative Net Change
biotechnology medical
Nektar (NKTR) Up on Positive New Data From Eczema Study
by Zacks Equity Research
Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.
LLYNegative Net Change NKTRPositive Net Change ANIKNegative Net Change ANVSNegative Net Change
biotechnology medical
"Blockbuster Status": 3 Bios to Buy and Hold
by Andrew Rocco
The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.
NVONegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechnology biotechs
Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up
by Zacks Equity Research
Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.
CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change LYRANegative Net Change
biotechnology medical
2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal
by Zacks Equity Research
2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.
BMYNegative Net Change
biotechnology biotechs pharmaceuticals
Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico
by Zacks Equity Research
Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.
DVAXNegative Net Change EXELNegative Net Change ETONNegative Net Change
biotechnology biotechs
Zoom Video Communications (ZM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ZMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up
by Zacks Equity Research
Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis.
CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology medical